Abivax (ABVX) EBT (2022 - 2026)

Abivax (ABVX) has reported EBT for 5 consecutive years, with -$56.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT fell 2.52% year-over-year to -$56.5 million; the TTM figure through Mar 2026 stood at -$379.2 million (down 90.06% YoY), while the FY2025 annual figure was -$384.5 million, down 104.2% from the prior year.
• EBT came in at -$56.5 million for Q1 2026 at Abivax, up from -$88.7 million in the prior quarter.
• The five-year high for EBT was -$41.8 million in Q2 2024, with the low at -$179.3 million in Q3 2025.
• Average EBT over 5 years is -$75.3 million, with a median of -$56.5 million recorded in 2026.
• Across the five-year window, EBT surged 69.33% in 2024 and tumbled 195.6% in 2025, its largest moves.
• Year by year, EBT stood at -$66.1 million in 2022, then slumped by 107.34% to -$137.1 million in 2023, then soared by 69.33% to -$42.0 million in 2024, then tumbled by 110.9% to -$88.7 million in 2025, then soared by 36.29% to -$56.5 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$56.5 million, -$88.7 million, and -$179.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.